Peptides DB
Research-centric peptide and protocol reference hub

Argireline record · updated 17h ago

Skin & aestheticsMuscle & body compGrade B · human evidenceResearch use only
All 16 studiesJump to the evidenceCompare
What is Argireline used for?

Argireline, or Acetyl Hexapeptide-3, is a synthetic peptide that has gained attention in cosmetic formulations due to its potential anti-aging effects. It is often compared to botulinum toxin, as it is believed to reduce the appearance of fine lines and wrinkles through a mechanism that involves inhibiting the release of neurotransmitters that cause muscle contraction. This action may lead to a temporary relaxation of facial muscles, thereby minimizing the formation of expression lines.

How it works: Inhibits neurotransmitter release

Primarily researched for · Skin & aestheticsRoute · Topical application

Development stage

where Argireline sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 48 registered trials. It describes the research record, not a recommendation.

Identity
NameArgireline
Chain length—
Molecular weight887 Da
FormulaC35H62N14O11S
Structure typeNot established
ClassAesthetic
Research levelModerate Research
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 71587772. No verified residue count for this compound.

Pharmacology
MechanismInhibits neurotransmitter release
RouteTopical application
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 26, 2026. How this works →
Research stats
Total studies16
Human / animal / cellular3 / 5 / 4
Highest trial phasePreclinical
Years covered2010–2026
Latest study6d ago
Publication history
20102026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

16 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
The eukaryote chromosome, a two-state system with interconversion by a volume phase transition.
FindingNot reported in abstract.
review2026Title only0.20
Metrnl Reduces Thrombosis and Acute Myocardial Injury Through Inhibition of Platelet Activation via CD36 Receptor Degradation.
FindingNot reported in abstract.
Animal2026Full text read0.70
Dissociation of the Glucose and Lipid Regulatory Functions of FoxO1 by Targeted Knockin of Acetylation-Defective Alleles in Mice.
TakeawayNot reported in abstract.
Animal2026Title only0.10
Is <i>Fusobacterium nucleatum</i> the key mediator between oral infections and systemic diseases? Mechanistic insights and therapeutic implications.
TakeawayFusobacterium nucleatum is identified as a key player in the link between oral infections and systemic diseases, with potential therapeutic strategies under exploration.
review2026Full text read0.70
Kaempferol from <i>Moringa oleifera</i> L. increases longevity and ameliorates efavirenz-induced functional senescence in <i>Drosophila melanogaster</i>.
FindingLC50 of Kaempferol was 338.60 mg/10 g diet.
Animal2026Full text read0.70
Enhancing myrcene biosynthesis in yeast through nuclear compartmentalization.
FindingFinal titer of 23.4 mg L-1 in flask-shaking fermentation.
In vitro2026Full text read0.70
Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues.
TakeawayThis study explores a new method for selectively targeting KAT2A in cancer, but specific results are not detailed in the abstract.
In vitro2026Title only0.20
Loss of ATP-Dependent Citrate Lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling.
FindingNot reported in abstract.
Human2026Full text read0.70
Mitochondrial metabolism and epigenetic crosstalk drive SASP.
FindingNot reported in abstract.
Animal2026Partial text0.50
Transdermal Delivery of Botulinum Toxin for the Management of Oily and Acne-Prone Skin Using TDA Technology.
FindingNot reported in abstract.
Human2026Full text read0.70
Cosmetic potential of Ganoderma lucidum (Reishi) extract in a topical cream formulation.
Finding861 μmol TE/g antioxidant activity for Reishi extract.
In vitro2026Full text read0.70
Cosmetic potential of Ganoderma lucidum (Reishi) extract in a topical cream formulation.
Finding861 μmol TE/g antioxidant activity for Reishi extract.
In vitro2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Argireline will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Argireline is discussed should be drawn from it.

Articles mentioning Argireline